Related Experiment Video
Updated: Jan 29, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule
T P Afra1, T Muhammed Razmi1, Sunil Dogra2
1Department of Dermatology, IQRAA International Hospital and Research Centre, Calicut, Kerala, India.
Abstract:
Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (September 23, 2014). It has got approval from Drug Controller General of India for marketing in India in 2017. The drug has drawn much attention from the practising dermatologists for its commendable safety profile and prescription convenience. Introduced initially as an orally administered small molecule in psoriasis patients, the drug has now been used in various other indications as evident by the recent surge in literature for its off-label uses. Being a relatively new drug in the treatment armamentarium of psoriasis and other inflammatory dermatoses; in this review, we will discuss various practical aspects of prescribing oral apremilast, based on the current and emerging literature.
Related Concept Videos
Molecules and Compounds
Types of Signaling Molecules
Behavior of Gas Molecules: Molecular Diffusion, Mean Free Path, and Effusion
Positive Regulator Molecules
Positive Regulator Molecules
Ions, Molecules, and Compounds

